X4 Pharma Q3 net loss $29.8M ($0.69/sh); cash runway to end 2028 after $240.3M financing

X4 Pharmaceuticals, Inc

2025-Q3 EPS reported -$2.87 vs consensus -$0.93 ▼ miss (-207.2%)

Q3 net product sales XOLREMDI $1.6M vs $0.6M YoY; net loss $0.69/sh vs $5.48/sh in Q3 2024.
Raised $240.3M gross via public offering and upsized private placement; cash runway extended to end of 2028.
50% workforce reduction yields ~$13M annualized cost savings; focus on Phase 3 4WARD chronic neutropenia trial.
Enrollment target for 4WARD increased to 176 patients; expected completion Q3 2026; sNDA potential in chronic neutropenia.
Deprioritized XOLREMDI commercialization for WHIM syndrome; John Volpone promoted to COO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.